Fox Chase Cancer Center News

PHILADELPHIA (June 28, 2021) – A Fox Chase Cancer Center researcher has received a grant of approximately half a million dollars from the National Institutes of Health (NIH) to identify disease-causing T cell defects. The work will also involve developing genome editing as an improved and more personalized form of treatment of immune-related diseases.

PHILADELPHIA (June 22, 2021)—A new study by researchers at Fox Chase Cancer Center found that patients with muscle-invasive bladder cancer can safely receive chemotherapy, even when their tumors are blocking their kidneys. The findings mean that patients with the most serious form of this common cancer can receive potentially life-extending treatment, usually without the need for additional invasive procedures.

PHILADELPHIA (June 21, 2021)—Researchers at Fox Chase Cancer Center have identified Musashi-2 (MSI2) protein as having the potential to both identify targeted therapies for certain patients with non-small cell lung cancer (NSCLC) and to serve as a target for the development of new therapies.

PHILADELPHIA (June 21, 2021)—Elizabeth Plimack, MD, MS, chief of the Division of Genitourinary Medical Oncology and professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, was recently appointed medical oncology editor for the journal European Urology.

PHILADELPHIA (June 18, 2021)—Three researchers from the Fox Chase Cancer Prevention and Control Program were recognized by Temple University with the Social & Behavioral Sciences Community Partner Outstanding Supervisor Award. This year’s honorees were Jennifer Barsky Reese, PhD; Linda Fleisher, PhD, MPH; and Suzanne M. Miller, PhD.

PHILADELPHIA (June 18, 2021)–Researchers at Fox Chase Cancer Center are using a powerful single nucleotide polymorphism-based chromosome microarray (CMA) to differentiate between benign and cancerous lipomatous tumors.

PHILADELPHIA (June 18, 2021)—A study from researchers at Fox Chase Cancer Center suggests that some breast cancer patients may be able to forgo certain testing procedures after neoadjuvant chemotherapy, which is chemotherapy given before other treatment, without increasing their risk of cancer returning.

PHILADELPHIA (June 18, 2021)—Fox Chase Cancer Center’s main, Buckingham, and East Norriton campuses have been awarded a three-year term of reaccreditation in radiation oncology as the result of a recent review by the American College of Radiology (ACR).